Cardior Pharmaceuticals GmbH

Cardior Pharmaceuticals is an academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world. Our lead development program is an oligonucleotide based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury - CDR-132X.